I-BET151 (GSK1210151A)
I-BET151 (GSK1210151A)是一种新型，选择性的BET抑制剂，作用于BRD2，无细胞试验中BRD3和BRD4，IC50分别为0.5 μM， 0.25 μM和0.79 μM。
I-BET151 (GSK1210151A) Chemical Structure
CAS: 1300031-49-5
客户使用Selleck的I-BET151 (GSK1210151A)发表文献51篇
产品质控
批次：
纯度：
99.99%
99.99
I-BET151 (GSK1210151A)相关产品
| 相关靶点 | BET p300/CBP BRPF bromodomain | 点击展开 |
|---|---|---|
| 相关化合物库 | 激酶抑制剂库 FDA药物库 天然产物库 已知活性药物库-I 生物活性库Ⅱ | 点击展开 |
相关信号通路图
Epigenetic Reader Domain抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| HT-29 | Function assay | 0.3125 uM to 5 uM | 24 hrs | Inhibition of BRD4 in human HT-29 cells assessed as reduction in c-Myc protein expression at 0.3125 uM to 5 uM uM after 24 hrs by Western blotting method | 25559428 |
| H929 | Apoptosis assay | ~1 μM | induces cell apoptosis | 24335499 | |
| RPMI8226 | Function assay | ~1 μM | induces cell cycle arrest | 24335499 | |
| KMS11 | Function assay | ~1 μM | induces cell cycle arrest | 24335499 | |
| KMS18 | Function assay | ~1 μM | induces cell cycle arrest | 24335499 | |
| KMS12BM | Function assay | ~1 μM | induces cell cycle arrest | 24335499 | |
| KMS12PE | Function assay | ~1 μM | induces cell cycle arrest | 24335499 | |
| H929 | Function assay | ~1 μM | induces cell cycle arrest | 24335499 | |
| BC3 | Function assay | 800 nM | reduces c-Myc protein levels | 23792448 | |
| BC1 | Function assay | 800 nM | reduces c-Myc protein levels | 23792448 | |
| BC3 | Function assay | 500 nM | induces cell-cycle arrest | 23792448 | |
| BC1 | Function assay | 500 nM | induces cell-cycle arrest | 23792448 | |
| UM-PEL-3 | Growth inhibitory assay | ~1 μM | IC50=180 nM | 23792448 | |
| UM-PEL-1 | Growth inhibitory assay | ~1 μM | IC50=210 nM | 23792448 | |
| U266 | Growth inhibitory assay | ~1 μM | IC50=950 nM | 23792448 | |
| MM1S | Growth inhibitory assay | ~1 μM | IC50=760 nM | 23792448 | |
| Jurkat | Growth inhibitory assay | ~1 μM | IC50=1220 nM | 23792448 | |
| Namalwa | Growth inhibitory assay | ~1 μM | IC50=970 nM | 23792448 | |
| BJAB | Growth inhibitory assay | ~1 μM | IC50=970 nM | 23792448 | |
| BCBL1 | Growth inhibitory assay | ~1 μM | IC50=330 nM | 23792448 | |
| BC3 | Growth inhibitory assay | ~1 μM | IC50=460 nM | 23792448 | |
| BC1 | Growth inhibitory assay | ~1 μM | IC50=220 nM | 23792448 | |
| A72 | Function assay | ~10 μM | reactivates latent HIV-1 | 23255218 | |
| A2 | Function assay | ~10 μM | reactivates latent HIV-1 | 23255218 | |
| MOLM13 | Apoptosis assay | ~100 μM | induces apoptosis | 21964340 | |
| MV4;11 | Apoptosis assay | ~100 μM | induces apoptosis | 21964340 | |
| HL60 | cytotoxicity assay | ~100 μM | IC50=890 nM | 21964340 | |
| MEG01 | cytotoxicity assay | ~100 μM | IC50=25 μM | 21964340 | |
| K562 | cytotoxicity assay | ~100 μM | IC50>100 μM | 21964340 | |
| HEL | cytotoxicity assay | ~100 μM | IC50=1 μM | 21964340 | |
| NOMO1 | cytotoxicity assay | ~100 μM | IC50=15 nM | 21964340 | |
| MOLM13 | cytotoxicity assay | ~100 μM | IC50=120 nM | 21964340 | |
| RS4;11 | cytotoxicity assay | ~100 μM | IC50=192 nM | 21964340 | |
| MV4;11 | cytotoxicity assay | ~100 μM | IC50=26 nM | 21964340 | |
| KMS12PE | Apoptosis assay | ~1 μM | induces cell apoptosis | 24335499 | |
| KMS12BM | Apoptosis assay | ~1 μM | induces cell apoptosis | 24335499 | |
| KMS18 | Apoptosis assay | ~1 μM | induces cell apoptosis | 24335499 | |
| KMS11 | Apoptosis assay | ~1 μM | induces cell apoptosis | 24335499 | |
| RPMI8226 | Apoptosis assay | ~1 μM | induces cell apoptosis | 24335499 | |
| U87MG | Function assay | ~10 μM | reduces U87MG cellular ATP with IC50 of 1.05 μM | 24496381 | |
| A172 | Function assay | ~10 μM | reduces cellular ATP with IC50 of 1.28 μM | 24496381 | |
| SW1783 | Function assay | ~10 μM | reduces cellular ATP with IC50 of 2.68 μM | 24496381 | |
| U87MG | Function assay | ~10 μM | increases proportion of cells in the G1/S transition | 24496381 | |
| RAW267.4 | Function assay | 1 μM | reduces IL-6 production induced by LPS | 24859008 | |
| RAW267.4 | Function assay | 1 μM | reduces the association between BRD4 and acetylated p65 | 24859008 | |
| Me007 | Growth inhibitory assay | ~100 μM | inhibits the growth | 24906137 | |
| SK-Mel-28 | Growth inhibitory assay | ~100 μM | inhibits the growth | 24906137 | |
| Mel-RMU | Growth inhibitory assay | ~100 μM | inhibits the growth | 24906137 | |
| Mel-JD | Growth inhibitory assay | ~100 μM | inhibits the growth | 24906137 | |
| Mel-RM | Growth inhibitory assay | ~100 μM | inhibits the growth | 24906137 | |
| Me007 | Apoptosis assay | ~100 μM | induces apoptosis | 24906137 | |
| SK-Mel-28 | Apoptosis assay | ~100 μM | induces apoptosis | 24906137 | |
| Mel-RMU | Apoptosis assay | ~100 μM | induces apoptosis | 24906137 | |
| Mel-JD | Apoptosis assay | ~100 μM | induces apoptosis | 24906137 | |
| Mel-RM | Apoptosis assay | ~100 μM | induces apoptosis | 24906137 | |
| Me007 | Function assay | 10 μM | induces cell cycle arrest by upregulation of p21 | 24906137 | |
| SK-Mel-28 | Function assay | 10 μM | induces cell cycle arrest by upregulation of p21 | 24906137 | |
| Mel-RMU | Function assay | 10 μM | induces cell cycle arrest by upregulation of p21 | 24906137 | |
| Mel-JD | Function assay | 10 μM | induces cell cycle arrest by upregulation of p21 | 24906137 | |
| Mel-RM | Function assay | 10 μM | induces cell cycle arrest by upregulation of p21 | 24906137 | |
| Me007 | Function assay | 10 μM | upregulates proapoptotic and cell cycle arrest genes | 24906137 | |
| SK-Mel-28 | Function assay | 10 μM | upregulates proapoptotic and cell cycle arrest genes | 24906137 | |
| Mel-RMU | Function assay | 10 μM | upregulates proapoptotic and cell cycle arrest genes | 24906137 | |
| Mel-JD | Function assay | 10 μM | upregulates proapoptotic and cell cycle arrest genes | 24906137 | |
| Mel-RM | Function assay | 10 μM | upregulates proapoptotic and cell cycle arrest genes | 24906137 | |
| HepG2 | Function assay | 18 hrs | Upregulation of ApoA1 expression in human HepG2 cells assessed as concentration required to increase 70% of luciferase activity after 18 hrs by luciferase reporter gene assay, EC170 = 0.09 μM. | 22386529 | |
| Raji | Function assay | 4 hrs | Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs, IC50 = 0.13 μM. | 24900758 | |
| MV4-11 | Growth inhibition assay | 72 hrs | Growth inhibition of human MV4-11 cells after 72 hrs by SRB assay, IC50 = 0.119 μM. | 25559428 | |
| MM1S | Growth inhibition assay | 72 hrs | Growth inhibition of human MM1S cells after 72 hrs by SRB assay, IC50 = 0.299 μM. | 25559428 | |
| HT-29 | Growth inhibition assay | 72 hrs | Growth inhibition of human HT-29 cells after 72 hrs by SRB assay, IC50 = 0.945 μM. | 25559428 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, IC50 = 0.0317 μM. | 26080064 | |
| MV4-11 | Cytotoxicity assay | 4 days | Cytotoxicity against human MV4-11 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay, IC50 = 0.162 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, IC50 = 0.226 μM. | 26080064 | |
| MOLM13 | Cytotoxicity assay | 4 days | Cytotoxicity against human MOLM13 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay, IC50 = 0.228 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, IC50 = 0.0317 μM. | 28463487 | |
| MV4-11 | Growth inhibition assay | 4 days | Growth inhibition of human MV4-11 cells after 4 days by WST-8 assay, IC50 = 0.162 μM. | 28463487 | |
| Rosetta2 DE3 | Function assay | 30 mins | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, IC50 = 0.226 μM. | 28463487 | |
| MOLM13 | Growth inhibition assay | 4 days | Growth inhibition of human MOLM13 cells after 4 days by WST-8 assay, IC50 = 0.228 μM. | 28463487 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0072 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.009 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.009 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0223 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0496 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Displacement of FAM-labeled ZBA248 from BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells after 30 mins by fluorescence polarization assay, Ki = 0.0748 μM. | 26080064 | |
| Rosetta2 DE3 | Function assay | 30 mins | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 1 (44 to 168 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, Ki = 0.009 μM. | 28463487 | |
| Rosetta2 DE3 | Function assay | 30 mins | Inhibition of FAM-labeled ZBA248 binding to recombinant human N-terminal His6-tagged BRD4 bromodomain 2 (333 to 460 residues) expressed in Rosetta2 DE3 cells after 30 mins by Flourescence polarization assay, Ki = 0.0748 μM. | 28463487 | |
| PBMC | Function assay | inhibits IL-6 with pIC50 of 6.7 | 22437115 | ||
| MV4;11 | Function assay | decreases the recruitment of BRD3/4 and impaired recruitment of CDK9 and PAF1 to the transcriptional start site | 21964340 | ||
| Rosetta2 DE3 | Function assay | Binding affinity to biotinylated BRD3 BD1 (24 to 144 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0298 μM. | 26080064 | ||
| Rosetta2 DE3 | Function assay | Binding affinity to biotinylated BRD3 BD2 (306 to 417 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0405 μM. | 26080064 | ||
| Rosetta2 DE3 | Function assay | Binding affinity to biotinylated BRD4 BD1 (44 to 168 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0528 μM. | 26080064 | ||
| Rosetta2 DE3 | Function assay | Binding affinity to biotinylated BRD2 BD1 (72 to 205 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0548 μM. | 26080064 | ||
| Rosetta2 DE3 | Function assay | Binding affinity to biotinylated BRD2 BD2 (349 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.0703 μM. | 26080064 | ||
| Rosetta2 DE3 | Function assay | Binding affinity to biotinylated BRD4 BD2 (333 to 460 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 0.215 μM. | 26080064 | ||
| Rosetta2 DE3 | Function assay | Binding affinity to biotinylated CREBBP (1043 to 1159 amino acid residues) (unknown origin) expressed in Rosetta2 DE3 cells by bio-layer interferometry method, Kd = 3.084 μM. | 26080064 | ||
| THP1 | Antiinflammatory assay | Antiinflammatory activity in human THP1 cells | 22386529 | ||
| MV4-11 | Function assay | Inhibition of BRD4 in human MV4-11 cells assessed as downregulation of BCL2 RNA expression by RNA-seq analysis | 29259751 | ||
| MV4-11 | Function assay | Inhibition of BRD4 in human MV4-11 cells assessed as downregulation of cMYC RNA expression by RNA-seq analysis | 29259751 | ||
| U-2 OS | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 29435139 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| DAOY | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 29435139 | ||
| BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
| SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
| BT-12 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 29435139 | ||
| MG 63 (6-TG R) | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
| fibroblast cells | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 29435139 | ||
| Rh41 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
| LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | I-BET151 (GSK1210151A)是一种新型，选择性的BET抑制剂，作用于BRD2，无细胞试验中BRD3和BRD4，IC50分别为0.5 μM， 0.25 μM和0.79 μM。 | ||||||
|---|---|---|---|---|---|---|---|
| 特性 | 优化I-BET151，使其有效及选择性靶向作用于BET，同时增强体内药代动力学和终末半衰期，以使延长体内研究。 | ||||||
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | I-BET151有效，选择性作用于多种不同蛋白类型，如COX-2, P450, Aurora B, GSK3β, PI3K-γ, GPCR, 离子通道，转运体。与I-BET762 (GSK525762A)类似, I-BET151 对BRD2, BRD3 和BRD4具有高的结合亲和力，Kd为0.02-0.1 μM,作用于人类外周血单核细胞（PBMC）和全血（WB）以及大鼠WB，显著抑制脂多糖刺激的IL-6细胞因子产生，IC50分别为0.16 μM, 1.26 μM, 和 1.26 μM。I-BET151(0.5 or 5 μM)作用于HL60核提取物，抑制BETs(BRD2, BRD3, BRD4, 和 BRD9)而非23种其他溴区蛋白结合到乙酰化的组蛋白肽。I-BET151有效作用于含不同 MLL融合的细胞系，如MV4;11, RS4;11, MOLM13, 和NOMO1 细胞， IC50为15-192 nM。一致的是，I-BET151完全消除MLL融合驱动的白血病（MOLM13）而非酪氨酸激酶激活（K562）驱动的白血病的菌落形成潜力。I-BET151也有效作用于液体培养和转化MLL-ENL或MLL-AF9的原代小鼠祖细胞的克隆形成实验。I-BET151作用于由不同的MLL融合（分别含MLL-AF9和MLL-AF4的MOLM13和MV4;11）而非K562细胞驱动的MLL融合细胞系，显著诱导细胞凋亡和G0/G1期停滞，可能是由于通过抑制BRD3/4，PAFc和SEC组分招募到转录起始位点（TSS），而抑制BCL-2，C-MYC和CDK6的转录。[1] | |||
|---|---|---|---|---|
| 激酶实验 | 荧光各向异性（FP）的配体位移检测 | |||
| 所有组分溶解在50 mM HEPES pH 7.4, 150 mM NaCl和 0.5 mM CHAPS组成的Buffer中，BRD 2/3/4终浓度为75 nM，荧光配体为5 nM。在Greiner 384孔黑色的低量微孔板中，使用Micro Multidrop 将10 μL反应混合物加入到含100 nL各种浓度I-BET151或DMSO空白对照（1%最终）的孔中，并在黑暗中室温下平衡60分钟。使用 Envision (lex=485 nm，lEM=530 nm；Dichroic=505 nM)读取荧光各向异性。 | ||||
| 细胞实验 | 细胞系 | MV4;11, MOLM13, NOMO1, RS4;11, HEL, HL60 和 K562 | ||
| 浓度 | 溶于DMSO, 终浓度为~100 μM | |||
| 孵育时间 | 24,或72小时 | |||
| 方法 | 使用多种不同浓度I-BET151在384孔或96孔板中处理细胞24或72小时。细胞生长抑制实验中，实验板每孔中加入与细胞培养基同等体积的CellTiter-Glo试剂，震荡约2分钟，然后在Analyst GT 或EnVision酶标仪上读取化学发光信号。细胞增殖实验中，每孔加入CellTiter-Aqueous One，然后实验板在37°C下温育4小时。在SpectraMax Gemini酶标仪上490 nm处读取吸光度。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | HP1α / HP1β / HP1γ FoxM1 / AURKB / Survivin / cyclin B / PLK1 α-SMA / Fibronectin / Collagen-1 |
|
30386240 | |
| 体内研究(In Vivo) | ||
| 体内研究活性 | I-BET151每天按30 mg/kg剂量处理小鼠，显著抑制鼠类MLL-AF9和人类MLL-AF4白血病肿瘤生长，显著延长寿命。[1] | |
|---|---|---|
| 动物实验 | Animal Models | 静脉注射MV4;11细胞的NOD-SCID小鼠,静脉注射MLL-AF9细胞的C57BL/6小鼠 |
| Dosages | ~30 mg/kg/day | |
| Administration | 腹腔注射 | |
化学信息&溶解度
| 分子量 | 415.44 | 分子式 | C23H21N5O3 |
| CAS号 | 1300031-49-5 | SDF | Download I-BET151 (GSK1210151A) SDF |
| Smiles | CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 83 mg/mL ( (199.78 mM)； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Ethanol : 83 mg/mL Water : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy I-BET151|I-BET151 ic50|I-BET151 price|I-BET151 cost|I-BET151 solubility dmso|I-BET151 purchase|I-BET151 manufacturer|I-BET151 research buy|I-BET151 order|I-BET151 mouse|I-BET151 chemical structure|I-BET151 mw|I-BET151 molecular weight|I-BET151 datasheet|I-BET151 supplier|I-BET151 in vitro|I-BET151 cell line|I-BET151 concentration|I-BET151 nmr|I-BET151 in vivo|I-BET151 clinical trial|I-BET151 inhibitor|I-BET151 Epigenetics inhibitor
